XML 61 R45.htm IDEA: XBRL DOCUMENT
v3.25.1

Commitments and Contingencies (Details Narrative) |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 08, 2024 USD ($) | Feb. 23, 2024 USD ($) | Aug. 27, 2023 USD ($) | Jun. 22, 2023 USD ($) | Feb. 05, 2021 USD ($) | Sep. 14, 2015 USD ($) | Dec. 24, 2013 USD ($) | Apr. 30, 2024 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Jan. 31, 2030 USD ($) | Mar. 14, 2025 USD ($) | Mar. 11, 2025 EUR (€) | Oct. 04, 2024 EUR (€) | Oct. 03, 2023 EUR (€) | Oct. 08, 2021 EUR (€)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  | $ 264,000 |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | $ 726,232 | $ 898,100 |  |  |  |  |  |
GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount related to milestone payment |  |  |  |  |  |  |  |  | 684,652 |  |  |  |  |  |  |
NDA Consulting Corp [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  | $ 4,000 |  | 12,000 | 16,000 |  |  |  |  |  |
Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual commitment |  |  |  |  |  |  |  |  | 526,000 |  |  |  |  |  |  |
Clinical Trial Monitoring Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 70,000 |  |  |  |  |  |  |
Clinical Research Support Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement expense |  |  |  |  |  |  |  |  | 0 | 16,165 |  |  |  |  |  |
Clinical Research Support Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement expense | $ 207,004 |  |  |  |  |  |  |  | 285,019 | 69,001 |  |  |  |  |  |
Total costs |  |  |  |  |  |  |  |  | 732,532 |  |  |  |  |  |  |
Collaboration Agreement [Member] | GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Inventory costs |  |  |  |  |  |  |  |  | 1,144,000 |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | 0 | 268,829 |  |  |  |  |  |
Collaboration Agreement [Member] | Bio Pharma Works LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |
Reimbursed expense |  |  |  |  |  |  |  |  | 39,200 | 120,000 |  |  |  |  |  |
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 104,000 |  |  |  |  | € 100,000 | € 500,000 | € 391,000
Research and development costs |  |  |  |  |  |  |  |  | 695,918 |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  | 210,362 | 226,150 |  |  |  |  |  |
Clinical Trial Research Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 147,239 |  |  |  |  |  |  |
Clinical Trial Research Monitoring [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 88,000 |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | 26,763 |  |  |  |  |  |  |
Work order agreement costs |  |  |  |  |  |  |  |  | 95,000 |  |  |  |  |  |  |
Clinical Trial Research Monitoring [Member] | MD Anderson Cancer Center Clinical [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 26,763 |  |  |  |  |  |  |
Clinical Trial Research Monitoring [Member] | Theradex Systems, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | 20,191 |  |  |  |  |  |  |
Work Order Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total costs |  |  |  |  |  |  |  |  | 49,455 |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 104,000 |  |  |  |  |  |  |
Work Order Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total costs |  |  |  |  |  |  |  |  | 89,323 |  |  |  |  |  |  |
Research and development costs |  |  |  |  | $ 335,000 |  |  |  | 10,642 | 20,240 |  |  |  |  |  |
Work Order Agreement [Member] | Theradex Systems, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total costs |  |  |  |  |  |  |  |  | 20,191 |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | 34,593 | 14,862 |  |  |  |  |  |
Work cost |  |  | $ 106,380 | $ 153,000 |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payment through services |  |  | 47.00% | 72.00% |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payment through software |  |  | 53.00% | 28.00% |  |  |  |  |  |  |  |  |  |  |  |
License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non refundable license issue royalty |  | $ 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum annual royalty payable |  |  |  |  |  |  |  |  | 30,000 |  |  |  |  |  |  |
Dosing of product |  | 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment for royalties |  | $ 1,225,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non refundable license issue royalty |  |  |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |
License Agreement [Member] | Due Each January 1 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum annual royalty payable |  | $ 25,643 |  |  |  |  |  | $ 25,643 |  |  | $ 30,000 |  |  |  |  |
Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 1,795,000 |  |  |  |  |  |  |
Research and development process costs |  |  |  |  |  |  |  |  | 75,643 |  |  |  |  |  |  |
Stock based compensation |  |  |  |  |  |  |  |  |  | 9,109 |  |  |  |  |  |
MRI Global [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  | 118,000 |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | 340,522 |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  | $ 23,308 | $ 32,307 |  |  |  |  |  |
Subsequent Event [Member] | Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual commitment |  |  |  |  |  |  |  |  |  |  |  | 526,000 |  |  |  |
Subsequent Event [Member] | Clinical Trial Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual commitment |  |  |  |  |  |  |  |  |  |  |  | 264,000 |  |  |  |
Subsequent Event [Member] | Clinical Trial Monitoring Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual commitment |  |  |  |  |  |  |  |  |  |  |  | 262,000 |  |  |  |
Subsequent Event [Member] | Collaboration Agreement [Member] | GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  | $ 264,000 |  |  |  |
Subsequent Event [Member] | Development Collaboration Agreement [Member] | GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected | € |  |  |  |  |  |  |  |  |  |  |  |  | € 3,095,000 |  |  |

X
- Definition Advance amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consulting and advisory quarterly cash fee. + References No definition available. + Details
Name: | LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Estimated work cost. + References No definition available. + Details
Name: | LIXT_EstimatedWorkCost
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of expected paymen through software. + References No definition available. + Details
Name: | LIXT_ExpectedPaymentThroughSoftware
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected payment in services. + References No definition available. + Details
Name: | LIXT_ExpectedPaymentinServices
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement expense. + References No definition available. + Details
Name: | LIXT_ReimbursementExpense
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty payable. + References No definition available. + Details
Name: | LIXT_RoyaltyPayable
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royaties percentage + References No definition available. + Details
Name: | LIXT_RoyatiesPercentage
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Work order agreement costs + References No definition available. + Details
Name: | LIXT_WorkOrderAgreementCosts
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_DeferredCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 954 -SubTopic 450 -Section 30 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478201/954-450-30-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 954 -SubTopic 450 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478201/954-450-30-3 + Details
Name: | us-gaap_HealthCareOrganizationHealthCareCostsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InventoryPartsAndComponentsNetOfReserves
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of noncash expense for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_ShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |